Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | SVP & Chief Legal Officer | September 13, 2011 | September 14, 2011 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date September 13, 2011 · Filed September 14, 2011
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 112,999 |
Ending reported balance
After 2011-09-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2011-09-13 · Exercise / conversion · Acquired 22,000 · Balance 134,999 Row 2 · 2011-09-13 · Sale · Disposed 22,000 · Balance 112,999 F1: Transaction made pursuant to Mr. Boger's company approved trading plan under Rule 10b5-1. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $18.75 · Expires 2011-09-23 | Direct | 0 |
Reported balance
After 2011-09-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2011-09-13 · Exercise / conversion · Disposed 22,000 · Balance 0 F3: Fully vested. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 5,021 |
Reported balance
Holding disclosure · report date 2011-09-13 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,021 |
| Common StockSEC Table I · non-derivative | IndirectTrustee of Trusts | 174,167 |
Reported balance
Holding disclosure · report date 2011-09-13 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 174,167 F2: Kenneth S. Boger is the trustee for trusts established for the benefit of the three adult children of Joshua S. Boger (a director of the issuer). |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. Boger's company approved trading plan under Rule 10b5-1.
F2: Kenneth S. Boger is the trustee for trusts established for the benefit of the three adult children of Joshua S. Boger (a director of the issuer).
F3: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 11, 2003 Filed Dec 15, 2003 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 1,920 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-03-000054 · edgar.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,920 F1 · shares: Stock grant made under 1996 Stock and Option Plan, vesting in 4 equal annual installments from 12/11/2003. Read SEC document |
| November 17, 2003 Filed Nov 17, 2003 17:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | PurchaseCommon Stock | 5,360 | $8.87 | $47,543.20 |
DisclosureSEC source: 0000875320-03-000048 · edgar.xml · nonDerivative · entry 1 BOGER KENNETH S · CIK 0001046336 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.